Srb4 inhibitors pertain to a specific class of chemical compounds that have been designed to selectively hinder the activity of the Srb4 protein. The Srb4 protein, a component of the RNA polymerase II mediator complex, plays a crucial role in the regulation of gene transcription. The mediator complex serves as an intermediary between transcription factors and RNA polymerase II, facilitating the initiation and elongation of RNA transcription. Within this complex, Srb4 is critical for the functional integrity of the mediator, ensuring effective transcriptional regulation.
The chemical structures of Srb4 inhibitors are typically characterized by molecular frameworks that allow them to bind to the Srb4 protein with a high degree of specificity. The goal of these inhibitors is to modulate the function of Srb4 without significantly affecting other proteins or cellular processes. The selectivity of these inhibitors is of utmost importance to ensure minimal off-target effects. Through various molecular interactions, including hydrogen bonding, hydrophobic interactions, and electrostatic forces, these inhibitors latch onto the Srb4 protein, impeding its function in the mediator complex. Advancements in structural biology and computational methodologies have played a pivotal role in the design and optimization of these inhibitors, allowing for a more detailed understanding of their interaction dynamics with the Srb4 protein. As a result, it is possible to fine-tune the chemical properties of these inhibitors to achieve desired outcomes in terms of potency, specificity, and stability.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits the RAF/MEK/ERK signaling pathway by targeting multiple kinases, including BRAF, VEGFR, and PDGFR, to block tumor cell proliferation and angiogenesis. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib is a multi-kinase inhibitor that targets VEGFR, PDGFR, FGFR, and others, inhibiting angiogenesis and tumor growth through disruption of signaling pathways. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Lenvatinib is a dual inhibitor of VEGFR and FGFR, reducing angiogenesis and tumor cell proliferation by blocking these receptor tyrosine kinases. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Ponatinib is a potent BCR-ABL inhibitor that also targets other kinases, inhibiting the growth of BCR-ABL-positive leukemia cells by interrupting signaling pathways. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits VEGFR, EGFR, and RET kinases, suppressing angiogenesis and tumor cell proliferation, particularly in medullary thyroid cancer. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib targets VEGFR, PDGFR, and other kinases, hindering angiogenesis and tumor growth through the inhibition of multiple signaling pathways. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Cabozantinib targets VEGFR, MET, and AXL kinases, disrupting angiogenesis and inhibiting tumor cell migration, invasion, and survival via multiple pathways. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib inhibits VEGFR, PDGFR, and FGFR, impairing angiogenesis and tumor cell growth by interfering with various receptor tyrosine kinase signaling pathways. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Nintedanib is a triple kinase inhibitor that targets VEGFR, FGFR, and PDGFR, thereby reducing angiogenesis and fibrosis through the disruption of these signaling pathways. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib selectively inhibits JAK1 and JAK2 kinases, suppressing inflammation and cytokine signaling, offering relief to patients with myelofibrosis and polycythemia vera. | ||||||